Generic drugmaker Mylan announced Tuesday it would formally launch its hostile bid to acquire Perrigo Co. on Monday, when it will ask shareholders of the over-the-counter drug specialist to ignore management’s recommendation against the proposal and agree to merge.
Mylan wants to exchange $75 in cash plus 2.3 Mylan shares for each Perrigo share, giving Perrigo shareholders a roughly 40 percent stake in the combined company.
The bid is unchanged from a proposal in late April that was strongly rejected by Perrigo as inadequate. Perrigo also has contended that its prospects are better if it remains independent.
Mylan’s current offer will not be raised, absent a competing bid, executive chairman Robert Coury wrote in a letter to Perrigo CEO Joseph Papa that was released Tuesday.
“This is a highly compelling offer in terms of the price, multiple being paid, accretion and long-term potential for value creation,” Mr. Coury said in his letter.
Mylan, which maintains its operations base in Cecil after reincorporating in the Netherlands earlier this year, said the closing date for the offer is Nov. 13. Mylan shareholders approved moving ahead with the tender offer in late August.
Mylan’s offer for Perrigo is worth considerably less now than it was in late April — roughly $27 billion versus some $35 billion, based on the number of Perrigo shares outstanding — as Mylan’s share price has dropped about 35 percent. Based on Mylan’s closing share price Tuesday, the cash and stock offer values Perrigo at about $187 per share, down from about $242.
But Mylan’s letter to Mr. Papa makes the case that Perrigo’s stock has been protected from stock market swings by Mylan’s interest, and that Perrigo shareholders can expect their shares to drop in value if the deal doesn’t go through.
Mylan has said it needs only more than 50 percent of Perrigo’s shares to be tendered in order to gain control of the company and eventually complete the merger.
Analysts have speculated that tendering less than 80 percent would make a merger more complicated and jeopardize cost synergies Mylan expects the acquisition would generate.
In his letter to Mr. Papa on Tuesday, Mr. Coury again disagreed with that assessment, saying synergies would not be affected.
Mylan’s shares added 67 cents Tuesday, or 1.39 percent, to close at $48.72. Perrigo rose $1.85, or 1.03 percent, to close at $180.65.
Patricia Sabatini: psabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.